Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin in first-line advanced or unresectable biliary tract carcinoma
2019-000944-82Phase 3Unknown
- Sponsor
- Merck & Co.
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer comparing Pembrolizumab plus gemcitabine/cisplatin with Placebo plus gemcitabine/cisplatin (2 arms). Primary endpoints: Overall Survival and Progression-free Survival. Status: unknown.
02
Drugs
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2019-000944-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000944-82.